Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Many drug companies have lost a lot of money betting on IFN over the last few decades. Biogen which had the parent patents in the 1980s made a ton of money on hepatitis and MS but there are now better therapies. But you know all this
So Tommy many drugs - most - can be delivered in saline as you know. (I thought you had a medical degree) . My understanding is AZ offered 7 million up front and given where we are they would not pay more. I used to work for AZ btw
Btw I am sorry you think what I write is “nonsense” and that I need to be more diligent. In my defence I did warn people that the phase 3 trials were likely to disappoint based on my own research. You can see my posts from back in the day.
So Jint as I am sure you realise the formulation is not crucial. I used to nebulise IFN into the lungs using saline and an off the shelf nebuliser. We could measure the IFN in the lungs immediately after administration and lung biopsies had developed viral resistance. Also there was some improved outcomes to RSV infections and respiratory herpes virus infections. The results were broadly similar to Synai gen’s data : improved outcomes but not good enough to pursue an MA. So the Synairgen formulation is not a gateway to the use of IFN in therapy - just my opinion.
But it seems you have other insights
Jint the patents are not to IFN as such and the therapeutic application claims are narrow andinevitably weak given the art. Anyone is entitled to sell IFN for treating respiratory disease as this has been done for 40 years.
Now the idea is not to target covid but viruses more generally there is no real protection in my view.
But maybe you know far more about this than I do and the technology is valuable and could be sold for millions.
What is your estimate of the value of the IP? I would be interested in your opinion
Spaceman what assets would you sell? The data? IFN patents expired long ago.
(When taxol which had clinical potential was struggling to get over the line it was essentially given away . And it was one of the most effective anti cancer drugs.)
Surrey, I agree with most of what you say save that experience suggests share price can really matter. It is hard for an acquirer to pay more than double the share price - at least a listed company. I hope I am wrong
I know you will hate me saying this but we were talking about autoantibodies in the 80s
https://pubmed.ncbi.nlm.nih.gov/38193358/#:~:text=Human%20autoantibodies%20(auto%2DAbs),Gresser%20from%201981%20to%201984.
Tommy
some successful drugs have taken even longer than 15 years. Taxol is probably the most famous example where the NCI failed to get its act together for 20 years and the BMS swooped in and sorted it out in 18 months. I have come across a couple of drugs that were developed in very short order but they have been repurposed.
Beta interferon in recombinant form has been going now been around for more than 40 years.( Don't shout at me for saying this)
Since I warned non- scientists that the results are likely to be disappointing this share has lost 96% of its value. People were trying to stop me posting then and continue to try to stop me now. Why should I give in to this pressure ?
DocDaneka look at my posts from 11Nov 22 everything I have written has been accurate I think. I did not day I am not a believer.
And what right do you have to judge and say I have not been subject to mys abuse. Take a long hard look at yourself
The answer to the question is a) I am interested b) I am disturbed by the scientific misinformation being spread by many which has resulted in some people losing money they could not afford.
Doc when I first raised this on 11 Nov 2022 I was subject to the most horrible abuse. I have been told I am a sad old lady, bitter, someone “who cannot keep a husband for obvious reasons” and now implied I am a loser for looking at this board during a western holiday on a Friday night. I have also been called a fantasist, an idiot, and a failure.
What is similar about the manifesto and Sakura accounts? I am intrigued. I thought I was the only person to say, when this share price was at its peak, that I had worked with IFN and it was unlikely to show more than marginal efficacy.